4.7 Article

Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 131, Issue 6, Pages 1565-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2013.01.006

Keywords

Birth cohort; double-blind randomized trial; nutritional intervention; cow's milk protein hydrolysate infant formulas; long-term allergy prevention

Funding

  1. Federal Ministry for Education, Science, Research and Technology [01 EE 9401-4]
  2. Federal Ministry for Environment (IUF) [FKZ 20462296]
  3. Nestle
  4. Mead Johnson
  5. Aerocrine
  6. AstraZeneca
  7. Novartis
  8. Deutsche Atemwegsliga
  9. Gesellschaft fur Padiatrische Allergologie
  10. Lions Club
  11. Federal Ministry of the Environment
  12. German Science Foundation (DFG)
  13. European Union
  14. Germany Ministry of Education and Research
  15. Phadia
  16. Euroimmune
  17. MSD
  18. Danone
  19. Hipp

Ask authors/readers for more resources

Background: The long-term effect of nutritional intervention with hydrolysate infant formulas on allergic manifestations in high-risk children is uncertain. Objective: We sought to investigate the effect of hydrolysate infant formulas on allergic phenotypes in children with family history of allergies at school age. Methods: We analyzed data from participants of the prospective German Infant Nutritional Intervention study after 10 years of follow-up. At birth, children were randomly assigned to receive, for the first 4 months, one of 4 blinded formulas as breast milk substitute, if necessary: partially hydrolyzed whey formula (pHF-W), extensively hydrolyzed whey formula (eHF-W), extensively hydrolyzed casein formula (eHF-C), or standard cow's milk formula. Outcomes were parent-reported, physician-diagnosed allergic diseases. Log-binomial regression models were used for statistical analysis. Results: The relative risk for the cumulative incidence of any allergic disease in the intention-to-treat analysis (n = 2252) was 0.87 (95% CI, 0.77-0.99) for pHF-W, 0.94 (95% CI, 0.83-1.07) for eHF-W, and 0.83 (95% CI, 0.72-0.95) for eHF-C compared with standard cow's milk formula. The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.00), 0.91 (95% CI, 0.76-1.10), and 0.72 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis (n = 988) effects were stronger. The period prevalence of AD at 7 to 10 years was significantly reduced with eHF-C in this analysis, but there was no preventive effect on asthma or allergic rhinitis. Conclusion: The significant preventive effect on the cumulative incidence of allergic diseases, particularly AD, with pHF-W and eHF-C persisted until 10 years without rebound, whereas eHF-W showed no significant risk reduction. There is insufficient evidence of ongoing preventive activity at 7 to 10 years of age.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available